b
r
c
base
synthes
use
efficaci
protocol
compound
show
vitro
antiplasmodi
activ
drugsensit
cq
drugresist
cq
r
strain
plasmodium
falciparum
nm
rang
particular
butylamino
pyrimidin
depict
lowest
ic
nm
valu
less
cq
cq
r
strain
structureeact
profil
bind
heme
moxohem
studi
bind
assay
dna
reveal
better
bind
target
parasit
type
rich
dna
compound
somewhat
cytotox
especi
cytostat
molecular
dock
analysi
pf
dhfr
allow
identif
stabil
interact
face
challeng
drug
resist
poor
health
system
lack
afford
safe
conveni
treatment
option
effici
treatment
malaria
one
devast
parasit
diseas
repres
unmet
medic
need
malaria
major
public
health
concern
countri
inhabit
billion
peopl
e
world
popul
respons
almost
million
death
everi
year
major
malaria
victim
develop
countri
pregnant
women
children
age
five
possess
littl
immunolog
protect
diseas
estim
result
million
new
annual
infect
worldwid
though
major
case
approxim
malaria
death
found
subsaharan
africa
diseas
increas
asia
latin
america
malaria
caus
protozoan
parasit
genu
plasmodium
infect
destroy
red
blood
cell
eventu
lead
death
untreat
persist
threat
emerg
multidrug
resist
plasmodium
falciparum
univers
chloroquin
resist
suspect
resist
artemisinin
lack
effect
appropri
afford
treatment
option
given
new
impetu
research
lead
broaden
rang
therapeut
target
thu
creat
new
armamentarium
drug
promis
antimalari
activ
coupl
understand
mode
action
may
lead
develop
new
gener
treatment
malaria
control
erad
common
featur
drug
base
quinin
presenc
quinolin
unit
usual
chloroquin
amodiaquin
chart
known
caus
parasit
death
block
polymer
toxic
heme
insolubl
nontox
pigment
hemozoin
result
cell
lysi
parasit
cell
autodigest
mode
action
base
drug
typifi
pyrimethamin
lead
compound
inhibit
p
falciparum
dihydrofol
reductas
pf
dhfr
enzym
requir
biosynthesi
tetrahydrofol
involv
biotransform
thymidyl
synthasecatalys
deoxyuridyl
deoxythymidyl
dump
dtmp
methyl
group
transfer
reaction
dna
biosynthesi
addit
number
polyamin
inhibit
ornithin
decarboxylas
activ
p
falciparum
bind
plasmodi
dna
recent
investig
hybrid
antimalari
agent
combin
pharmacophor
antimalari
activ
found
less
prone
resist
parasit
thu
offer
effect
mean
overcom
problem
drug
resist
envisag
link
unit
critic
antimalari
activ
divers
function
later
side
chain
antimalari
moieti
aminopyrimidin
might
furnish
conjug
hybrid
capabl
show
use
antimalari
activ
commun
report
synthesi
set
compound
possess
basic
hydrophob
well
hydrogen
bond
substitu
requir
target
either
heme
well
dna
thu
provid
new
antimalari
agent
activ
chloroquin
resist
strain
p
falciparum
evalu
antiplasmodi
activ
cytotox
cytostat
activ
bind
studi
dna
heme
monomer
well
moxo
dimer
use
uvevis
fluoresc
spectrophotometri
well
nmr
analysi
compound
synthes
outlin
scheme
via
common
intermedi
one
prepar
hclcatalyz
biginelli
condens
appropri
aldehyd
r
cho
alkylacetoacet
r
ch
coor
urea
dehydrogen
use
pyridinium
chlorochrom
dcm
furnish
pyrimidinon
reflux
pocl
yield
upon
nucleophil
substitut
reaction
appropri
gave
synthet
use
manner
structur
establish
basi
spectral
h
nmr
c
nmr
ms
ft
ir
well
microanalyt
analysi
yield
report
tabl
antiplasmodi
activ
pyrimidin
link
cq
describ
literatur
albeit
relat
one
dhpm
previous
report
use
synthet
protocol
shown
scheme
allow
consider
diversif
around
pyrimidin
core
conduct
sar
analysi
vitro
antiplasmodi
activ
determin
primari
secondari
screen
cq
cq
r
strain
p
falciparum
half
maxim
inhibitori
concentr
ic
summaris
tabl
fig
evid
compound
antiplasmodi
activ
nm
rang
cq
r
strain
p
falciparum
case
activ
found
even
superior
cq
systemat
variat
length
well
natur
spacer
connect
pharmacophor
discern
use
trend
antiplasmodi
activ
analog
compar
bear
linear
alkyl
spacer
reveal
increas
antiplasmodi
activ
increas
length
spacer
methylen
group
tabl
lengthen
spacer
chain
length
result
signific
reduct
activ
cq
r
well
cq
strain
replac
phenyl
group
methyl
group
creat
result
nearli
time
increas
antiplasmodi
activ
ic
nm
cq
strain
fact
compound
found
tabl
activ
compound
seri
cq
strain
howev
exhibit
high
resist
factor
within
seri
time
less
activ
cq
cq
r
strain
replac
ethyl
ester
isopropyl
ester
gener
show
decreas
vitro
antiplasmodi
activ
cq
strain
although
revers
trend
observ
cq
r
strain
especi
case
replac
phenyl
pnitrophenyl
onitrophenyl
group
addit
incorpor
isopropyl
ester
result
increas
activ
order
render
potent
ic
nm
time
potent
cq
tabl
compound
result
accord
trend
observ
case
n
nbi
alkan
diamin
wherein
alkyl
spacer
consist
four
carbon
atom
show
optimum
potenc
better
antiplasmodi
activ
phenylsubstitut
pyrimidin
compound
cq
r
strain
may
attribut
optim
fit
compound
activ
site
pfdhfr
lead
favor
conform
pp
interact
heme
function
moreov
introduct
nitro
substitu
phenyl
ring
posit
pyrimidin
core
result
signific
increas
antiplasmodi
activ
well
resist
cq
r
strain
although
littl
effect
activ
cq
strain
tabl
also
correspond
mor
pnitro
deriv
show
consider
variat
antiplasmodi
activ
tabl
comparison
compound
ident
spacer
reveal
pno
substitut
ic
nm
activ
omno
substitut
compound
respect
less
activ
unsubstitut
ethyl
ester
analog
comparison
butyl
spacer
analog
suggest
ono
phenyl
deriv
potent
mno
counterpart
well
ethyl
ester
analog
cq
r
strain
compound
found
activ
compound
seri
cq
r
strain
antiplasmodi
activ
ic
nm
time
cq
ic
nm
compar
artesun
ic
nm
tabl
compar
ic
nm
possess
branch
chain
spacer
ident
carbon
linear
spacer
analog
ic
nm
tabl
led
signific
decreas
activ
thu
compound
display
decreas
activ
compar
cq
r
strain
likewis
possess
branch
spacer
depict
decreas
ic
nm
tabl
activ
linear
alkyl
spacer
analog
tabl
higher
compar
branch
chain
spacer
antiplasmodi
activ
latter
cq
cq
r
strain
increas
also
show
increas
resist
factor
tabl
replac
linear
chain
spacer
oand
plink
aryl
group
respect
led
much
higher
ic
tabl
valu
compar
former
cq
r
strain
moder
activ
observ
case
cq
strain
find
could
attribut
increas
steric
bulk
affect
interact
iron
center
heme
compound
corrobor
perform
titrat
monomer
heme
molar
ratio
heme
henc
flexibl
chain
length
steric
constraint
spacer
link
quinolin
moieti
pyrimidin
unit
seem
play
role
antiplasmodi
activ
deriv
although
vitro
activ
especi
ic
nm
superior
cq
ic
nm
cq
r
strain
compound
suffer
high
clogp
valu
tabl
suggest
fact
possess
limit
aqueou
solubl
fact
seriou
limit
view
recent
advanc
formul
method
antivir
activ
compound
activ
cq
r
strain
also
evalu
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
vero
cell
cultur
ii
herp
simplex
viru
ko
herp
simplex
g
vaccinia
viru
vesicular
stomat
viru
herp
simplex
tk
ko
acv
r
cytomegaloviru
varicellazost
viru
hel
cell
cultur
iii
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
hela
cell
cultur
iv
influenza
viru
influenza
b
viru
mdck
cell
cultur
v
felin
corona
viru
fipv
felin
herp
viru
activ
crfk
cell
cultur
si
tabl
unfortun
signific
antivir
activ
note
subtox
concentr
compound
somewhat
cytotox
differ
cell
line
confluent
nonprolifer
cultur
especi
cytostat
prolifer
veromdckcrfk
cell
cultur
chloroquin
shown
inhibit
hiv
blockad
viral
entri
via
inhibit
endosom
acidif
compound
len
p
r
also
test
well
si
tabl
human
tlymphocyt
cem
cell
cultur
howev
none
compound
activ
subtox
concentr
gener
compound
exhibit
rel
high
cytostat
activ
display
fairli
safe
select
index
except
tabl
rang
mdck
cell
cultur
activ
compound
ic
valu
nm
cq
r
strain
exhibit
highest
select
index
si
ic
valu
nm
cq
r
strain
exhibit
high
select
index
howev
ic
valu
nm
toxic
select
index
plausibl
mechan
vitro
antiplasmodi
action
cq
r
strain
investig
found
potent
seri
compound
report
herein
ic
nm
ic
nm
compound
also
expect
bind
heme
fe
iii
ppix
hydroxo
aqua
complex
ferriprotoporphyrin
ix
solut
inhibit
aggreg
bhematin
much
way
cq
higher
clogp
valu
tabl
compound
higher
cq
necessit
use
aqueou
dmso
solvent
also
aqueou
dmso
solut
heme
expect
monomer
pure
aqueou
solut
exist
aggreg
form
known
cq
bind
heme
dimer
moxo
heme
vitro
also
inhibit
format
bhematin
vitro
analog
hemozoin
therefor
bind
assay
also
extend
heme
dimer
also
interact
monomer
heme
follow
spectrophotometr
titrat
ph
approxim
ph
food
vacuol
describ
previous
spectral
chang
fig
si
figur
upon
addit
increas
amount
mm
solut
heme
mm
hepe
buffer
ph
show
substanti
decreas
intens
fe
iii
ppix
soret
band
nm
shift
absorpt
maximum
longer
wavelength
qband
nm
metalloporphyrin
also
decreas
intens
si
figur
sharp
isosbest
point
observ
nm
ph
nm
ph
associ
constant
complex
form
monomer
fe
iii
ppix
ph
calcul
titrat
data
present
tabl
associ
constant
fig
found
greater
log
k
log
k
decreas
appar
ph
caus
fairli
modest
decreas
log
k
valu
indic
strong
bind
heme
even
acid
ph
bind
also
assess
h
nmr
titrat
heme
thu
h
nmr
spectrum
depict
consider
broaden
signal
condit
dmsod
record
inconclus
variat
chemic
shift
signal
correspond
quinolin
unit
clear
fig
upon
addit
heme
stoichiometri
stabl
complex
monomer
heme
ph
deduc
job
plot
si
figur
absorb
nm
got
maximum
mole
fraction
approach
good
agreement
associ
constant
log
k
valu
correspond
stabl
heme
speci
present
solut
obtain
fit
titrat
data
hyp
spec
nonlinear
least
squar
fit
programm
measur
log
k
valu
tabl
also
good
agreement
valu
report
literatur
cq
thu
format
synthet
fe
iii
complex
demonstr
suggest
inhibit
format
bhematin
presum
result
antiplasmodi
activ
compound
fashion
similar
cq
titrat
constant
concentr
heme
aqueou
naoh
solut
physiolog
ph
plasmodi
food
vacuol
allow
understand
interact
moxo
heme
addit
increas
amount
solut
moxo
heme
absorb
soret
band
nm
decreas
appreci
signific
red
shift
nm
fig
associ
constant
stoichiometri
determin
titrat
data
present
tabl
calcul
associ
constant
log
k
greater
log
k
correspond
stoichiometri
moxo
heme
complex
comparison
associ
constant
monomer
moxo
heme
reveal
compound
bind
strongli
moxo
heme
monomer
heme
inhibit
hemozoin
format
block
grow
face
heme
result
observ
antiplasmodi
activ
compound
also
screen
vitro
inhibit
bhematin
format
use
bhematin
inhibitori
assay
order
confirm
mechan
action
base
interfer
heme
detoxif
process
shown
tabl
gener
correl
antiplasmodi
activ
inhibit
bhematin
format
generalis
hold
compound
spite
bhematin
inhibit
tabl
one
least
activ
ic
nm
cq
r
ic
nm
cq
compound
seri
howev
must
note
antiplasmodi
activ
depend
upon
bhematin
inhibit
also
factor
degre
accumul
drug
food
vacuol
show
dose
depend
inhibit
bhematin
format
si
figur
ic
valu
lower
report
cq
quinin
thu
demonstr
better
abil
interact
fe
iii
ppix
overal
compound
show
strong
bhematin
inhibit
seem
prefer
mode
action
dna
bind
consid
previous
one
possibl
mechan
antiplasmodi
activ
studi
use
spectrophotometri
spectrofluorimetri
dna
melt
viscometri
etc
recent
deriv
shown
interact
dna
presum
ionic
interact
phosphat
group
dna
proton
amin
site
result
stabil
helic
configur
dna
thermal
denatur
addit
interact
aromat
nucleus
drug
nucleotid
base
might
also
contribut
bind
plasmid
dna
cq
result
elev
thermal
melt
temperatur
dna
addit
effect
therefor
investig
bind
activ
seri
toward
gc
rich
calf
thymu
dna
ct
dna
well
rich
dna
stepwis
addit
small
increment
dna
solut
compound
constant
concentr
well
physiolog
ph
fig
b
progress
decreas
characterist
quinolin
ring
absorpt
nm
attribut
intercal
quinolin
dna
indic
isosbest
point
nm
indic
spectra
limit
system
ie
spectra
free
complet
bound
drug
intersect
permit
select
singl
wavelength
studi
complex
format
bind
constant
log
k
calcul
benesiehildebrand
equat
suggest
strong
interact
ct
dna
comparison
bind
constant
reveal
bind
time
strongli
ct
dna
alter
dna
base
composit
see
effect
drug
bind
studi
interact
gc
rich
ct
dna
fluorometr
titrat
emiss
band
nm
fig
decreas
intens
increas
concentr
eventu
get
complet
quench
bind
constant
log
k
calcul
fluoresc
data
similar
titrat
rich
dna
log
k
reveal
higher
affin
toward
rich
dna
unlik
cq
known
interact
strongli
gc
rich
dna
strong
interact
pyrimidin
analog
rich
dna
suggest
compound
might
target
parasit
dna
unusu
high
content
addit
bhematin
inhibit
bind
ligand
nucleic
acid
dna
especi
rich
dna
may
possibl
induc
conform
chang
depend
upon
strength
mode
interact
nucleic
acid
thu
result
increas
thermal
denatur
temperatur
observ
cq
groov
bind
electrostat
bind
phosphat
backbon
dna
give
rise
small
chang
thermal
denatur
temperatur
compar
intercal
pathway
due
stabil
watson
crick
base
pair
duplex
direct
evalu
strength
interact
dna
thermal
behavior
si
figur
ct
dna
presenc
drug
evalu
thermal
denatur
temperatur
ct
dna
c
presenc
record
increas
dt
c
c
respect
si
tabl
suggest
primari
groov
bind
andor
partial
interc
natur
interact
mani
antiplasmodi
agent
known
interact
pf
dhfr
antiplasmodi
activ
especi
tabl
vitro
antiplasmodi
activ
cytotox
resist
factor
select
index
compound
ic
pyrimethamin
chart
known
produc
antiplasmodi
effect
bind
pf
dhfr
best
known
lead
compound
inhibitori
activ
worth
compar
perform
compound
design
work
use
molecular
dock
method
crystal
structur
pdb
id
structur
wildtyp
pf
dhfrt
complex
nadph
dump
consid
molecular
dock
analysi
appropri
prepar
protein
structur
pf
dhfr
dock
carri
fig
show
top
score
bind
pose
activ
site
pf
dhfr
dock
score
much
better
lead
compound
origin
improv
dock
score
trace
increas
number
stabil
interact
pf
dhfr
comparison
interact
pf
dhfr
show
hydrogen
bond
interact
residu
two
interact
common
well
addit
show
hydrogen
bond
interact
residu
addit
stabil
interact
ensur
adopt
slightli
differ
improv
pose
comparison
improv
interact
consid
determinist
factor
improv
antiplasmodi
activ
efficaci
transform
convert
readili
avail
dhpm
base
present
compound
show
antiplasmodi
activ
ident
superior
cq
structureeact
relationship
drawn
lead
identif
least
one
compound
lead
compound
seri
test
compound
depict
antivir
activ
cytotox
bind
interact
repres
potent
compound
heme
moxo
heme
use
uvevis
nmr
experi
furnish
log
k
valu
ident
cq
bind
point
stoichiometri
stabl
complex
solut
dna
gc
rich
bind
affin
use
absorpt
spectrofluorometr
data
indic
stronger
interact
fold
ct
dna
howev
show
higher
affin
toward
rich
dna
suggest
target
parasit
rich
dna
addit
bhematin
inhibit
possibl
mode
action
compound
dna
melt
experi
suggest
primari
groov
bind
andor
partial
interc
natur
interact
ct
dna
thu
strong
electrostat
interact
newli
design
pyrimidin
analog
rich
dna
blockag
heme
polymeris
complex
drug
heme
contribut
observ
antimalari
activ
nano
molar
rang
molecular
dock
analysi
activ
site
pf
dhfr
indic
superior
bind
compar
thu
drug
act
multipl
target
heme
enzym
involv
biosynthesi
dna
dhfr
parasit
dna
account
high
antiplasmodi
activ
liquid
reagent
driedpurifi
follow
recommend
dri
agent
andor
distil
molecular
siev
thf
dri
nabenzophenon
ketyl
nitrogen
h
nmr
mhz
c
mhz
nmr
spectra
record
cdcl
multinuclear
jeol
spectromet
chemic
shift
report
part
per
million
rel
intern
tetramethylsilan
tm
h
nmr
chloroform
cdcl
c
nmr
mass
spectra
record
indian
institut
integr
medicin
csir
jammu
electron
impact
ev
bruker
dalton
esquir
spectromet
element
analysi
perform
flash
ea
thermo
electron
corpor
analyz
depart
chemistri
guru
nanak
dev
univers
amritsar
result
quot
ir
record
ftir
shimadzu
fouriertransform
spectrophotomet
rang
cm
use
chloroform
medium
melt
point
determin
open
capillari
uncorrect
monitor
progress
reaction
comparison
purpos
thin
layer
chromatographi
tlc
perform
precoat
aluminum
sheet
merck
mm
use
appropri
solvent
system
chromatogram
visual
uv
light
column
chromatographi
silica
gel
mesh
employ
eluent
ethyl
acetatehexan
ethyl
acet
methanol
mixtur
stir
solut
mmol
potassium
carbon
mmol
dri
thf
ml
solut
appropri
mmol
dri
thf
ml
ad
reaction
mixtur
stir
h
room
temperatur
reaction
mixtur
filter
thf
remov
vacuum
residu
purifi
column
chromatographi
use
meoh
etoac
eluent
obtain
correspond
recrystal
dcmhexan
use
procedur
follow
compound
isol
stir
solut
appropri
dri
thf
ml
mixtur
molar
ratio
potassium
carbon
dri
acetonitril
ad
reaction
mixtur
reflux
h
filter
acetonitril
remov
vacuum
residu
purifi
column
chromatographi
use
etoachexan
eluent
give
recrystal
dcmhexan
yellow
solid
rf
hexaneetoac
two
clone
p
falciparum
use
clone
known
sensit
antiplasmodi
b
strain
origin
thailand
resist
chloroquin
pyrimethamin
sensit
mefloquin
cultur
natur
asynchron
ring
stage
maintain
continu
log
phase
growth
medium
supplement
wash
human
erythrocyt
mm
hepe
nm
nahco
albumaxii
lipidrich
bovin
serum
albumin
gibco
grand
island
ny
cm
cultur
assay
conduct
c
atmospher
co
balanc
n
stock
drug
solut
prepar
dmso
dimethylsulfoxid
mgml
compound
dilut
appropri
concentr
use
complet
medium
supplement
nm
cold
hypoxanthin
albumaxii
assay
perform
steril
microtitr
plate
plate
contain
ml
parasit
cultur
parasitemia
hematocrit
compound
test
triplic
parasit
growth
compar
control
blank
uninfect
erythtocyt
well
h
incub
c
bq
h
hypoxanthin
ad
well
cultur
incub
h
harvest
onto
glassfib
filter
mat
radioact
count
use
wallac
microbeta
scintil
counter
result
record
count
per
minut
cpm
per
well
drug
concentr
control
blank
well
percentag
inhibit
calcul
comparison
blank
control
well
ic
valu
calcul
use
graph
pad
prism
preliminari
screen
use
strain
compound
test
concentr
mgml
compound
affect
parasit
growth
mg
ml
classifi
inact
mgml
compound
design
partial
activ
mgml
compound
classifi
activ
evalu
threefold
serial
dilut
repeat
test
secondari
screen
clone
line
use
compound
dilut
threefold
differ
concentr
appropri
start
concentr
base
preliminari
screen
ic
determin
sigmoid
dose
respons
analysi
use
graph
pad
prism
assay
ic
ic
valu
parasit
line
determin
known
antiplasmodi
chloroquin
artesun
antivir
assay
except
antihuman
immunodefici
viru
hiv
assay
base
inhibit
virusinduc
cytopath
hel
herp
simplex
viru
type
g
vaccinia
viru
vesicular
stomat
viru
vero
coxsacki
punta
toro
viru
hela
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
mdck
influenza
b
viru
cell
cultur
confluent
cell
cultur
microtit
plate
inocul
cell
cultur
inhibitori
ccid
viru
ccid
viru
dose
infect
cell
cultur
presenc
vari
concentr
test
compound
viral
cytopath
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antihiv
activ
antiprolif
activ
evalu
strain
iiib
strain
rod
human
tlymphocyt
cem
cell
cultur
briefli
viru
stock
titrat
cem
cell
express
cell
cultur
infect
dose
ccid
cem
cell
suspend
cultur
medium
cellsml
infect
hiv
ccid
immedi
viral
exposur
ml
cell
suspens
place
well
flatbottom
microtit
plate
contain
variou
concentr
test
compound
incub
period
c
giant
cell
format
microscop
determin
compound
test
parallel
cytostat
activ
uninfect
cem
cell
bind
stoichiometri
drug
monomer
moxo
dimer
heme
monitor
uvevis
spectrophotometri
use
job
method
continu
variat
concentr
drug
heme
solut
kept
constant
chang
absorb
nm
monomer
nm
dimer
monitor
function
mole
fraction
well
plate
contain
mixtur
ml
mgml
hemin
chlorid
dissolv
dmso
ml
sodium
acet
buffer
ph
ml
differ
concentr
drug
solut
ml
solvent
control
incub
c
h
plate
centrifug
rpm
min
supernat
discard
remain
pellet
resuspend
ml
dmso
elimin
unreact
hemin
plate
centrifug
supernat
similarli
discard
precipit
dissolv
ml
n
naoh
absorb
read
nm
percentag
inhibit
ferriprotoporphyrin
ix
biomineralis
calcul
use
formula
ic
valu
determin
use
graph
pad
prism
dna
bind
studi
stock
solut
mm
prepar
ar
grade
methanol
dna
bind
experi
carri
make
dilut
stock
buffer
methanol
stock
solut
dna
prepar
dissolv
dna
pellet
te
buffer
mm
trisehcl
mm
edta
ph
dna
concentr
estim
absorb
intens
nm
known
molar
absorpt
coeffici
valu
dm
mol
cm
puriti
dna
establish
ratio
absorb
intens
nm
nm
observ
ratio
ensur
dna
free
protein
nm
variou
temperatur
presenc
absenc
drug
ratio
dna
drug
ramp
rate
cmin
dmsote
buffer
ph
mm
nacl
shimadzu
pc
spectrophotomet
equip
peltier
thermo
regul
thermal
melt
temperatur
calcul
plot
dadt
vs
temperatur
use
microsoft
excel
molecular
dock
analysi
carri
use
flexx
molecular
dock
modul
flexx
avail
sybyl
softwar
packag
tripos
dock
approach
adopt
increment
construct
algorithm
identifi
appropri
pose
substrat
activ
site
enzym
gener
possibl
pose
substrat
activ
site
pose
obtain
analysi
adopt
similar
bind
mode
enzym
caviti
henc
top
score
pose
consid
analysi
perform
analysi
crystal
structur
wildtyp
plasmodium
falciparum
dihydrofol
reductasethymidyl
synthas
pfdhfrt
complex
nadph
dump
download
protein
data
bank
pdb
subject
protein
prepar
receptor
descript
structur
substrat
prepar
first
build
molecul
optim
structur
use
tripo
forc
field
ionic
tautomer
state
substrat
consid
perform
molecular
dock
analysi
pose
shown
fig
includ
neutral
state
substrat
activ
site
enzym
